Has Align Technology (ALGN) Fallen Too Far After Recent Share Price Pullback?

• If you are wondering whether Align Technology's current share price reflects its true worth, the recent moves in the stock make that question especially timely.
• The shares last closed at US$178.40, with a 7 day return of a 9% decline, a 30 day return of 7.3% and a 1 year return of 2.9%. These sit against a 3 year return of a 41.1% decline and a 5 year return of a 68.7% decline.
• These mixed returns have come as Align continues to feature in discussions around clear aligner adoption, competitive pressures in orthodontics and how investors weigh up growth potential against previous share price declines. Recent commentary has focused on how sentiment around the business model and sector trends may be influencing risk perception rather than any single short term event.
• Simply Wall St currently gives Align Technology a valuation score of 1 out of 6. The next sections will walk through the standard valuation checks that lead to that score and then finish with a more rounded way to think about what the stock might be worth.

Align Technology scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Align Technology Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes projected future cash flows, then discounts them back to today to estimate what the entire business might be worth right now. It is essentially asking what you would pay today for all the cash Align Technology could generate in the future.

Align Technology reported last twelve month Free Cash Flow of about $459 million. Using a 2 Stage Free Cash Flow to Equity model, analysts and extrapolated estimates point to Free Cash Flow of $851.857 million in 2029, with a series of projected cash flows between 2026 and 2035 that are discounted back to today using Simply Wall St’s assumptions.

Putting these cash flows together, the model arrives at an estimated intrinsic value of around $205.23 per share. Compared with the recent share price of $178.40, the DCF outcome suggests the stock is trading at about a 13.1% discount, which indicates that, on this measure, it is undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Align Technology is undervalued by 13.1%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Align Technology.

Approach 2: Align Technology Price vs Earnings

For profitable companies, the P/E ratio is a useful guide because it links what you pay for each share directly to the earnings that business is currently generating. It gives you a quick sense of how many dollars of price the market is attaching to each dollar of earnings.

What counts as a "normal" or "fair" P/E depends on what investors expect for future growth and how much risk they see in those earnings. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher uncertainty usually points to a lower one.

Align Technology currently trades at a P/E of 31.1x, compared with the Medical Equipment industry average of about 23.3x and a peer average of 22.5x. Simply Wall St also calculates a proprietary "Fair Ratio" of 25.3x for Align, which reflects factors such as earnings growth, industry, profit margins, market cap and company specific risks.

This Fair Ratio can be more informative than a simple comparison with peers or the industry, because it adjusts for the company’s own characteristics rather than assuming all companies deserve the same multiple. With a current P/E of 31.1x versus a Fair Ratio of 25.3x, the shares screen as overvalued on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Align Technology Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives let you turn your view of Align Technology into a clear story that connects assumptions about future revenue, earnings and margins to a forecast, a Fair Value, and then a simple comparison with the current price, all inside Simply Wall St’s Community page where millions of investors share views. One investor might build an Align story around a higher Fair Value of about US$240 that assumes faster revenue growth, a 16.0% profit margin and a 25.15x future P/E. Another might lean toward a lower Fair Value closer to US$152.60 that uses more conservative revenue growth of 3.50%, a 15.85% margin and a 17.72x future P/E. As new news or earnings arrive these Narratives update automatically so you can quickly see whether your story still stacks up against the latest numbers.

For Align Technology however we will make it really easy for you with previews of two leading Align Technology Narratives:

🐂 Align Technology Bull Case

Fair value: US$201.69 per share

Current price vs this fair value: about 11.5% below that narrative fair value

Revenue growth assumption: 4.94% per year

• Focuses on clear aligner adoption across new clinical segments and international markets, with analysts using revenue growth, margin expansion and a lower future P/E of 23.6x to support a US$201.69 fair value.
• Highlights investments in digital workflow, automation and AI driven planning, alongside marketing and partnerships, as key factors supporting higher earnings quality and efficiency over time.
• Flags risks around macro conditions, product mix moving to lower price points, competition from traditional braces and other aligner providers, and scanner demand as reasons to stress test the narrative against personal assumptions.

🐻 Align Technology Bear Case

Fair value: US$154.62 per share

Current price vs this fair value: about 15.4% above that narrative fair value

Revenue growth assumption: 4.80% per year

• Frames Align as a premium orthodontics provider in a cost sensitive world, where inflation, pressure on discretionary spending and lower cost competitors test how much pricing power is sustainable.
• Emphasizes that Invisalign, iTero and software tools still support clinical outcomes and practitioner loyalty, but questions how far this technology and brand strength can offset price competition and regional economic differences.
• Suggests that the stock already reflects meaningful expectations for margins, brand durability and clinical trust, so execution risk and sensitivity to consumer demand are central to any cautious stance.

If you want to go beyond these quick previews and see the full assumptions, risks and valuation logic set out by real investors in detail, you can step through the complete Align Technology narratives on Simply Wall St to pressure test your own view before making any decisions.

Do you think there's more to the story for Align Technology? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com